GLUE
Monte Rosa Therapeutics Inc.
$6.53
+$0.20(+3.16%)
55
Overall
65
Value
45
Tech
--
Quality
Market Cap
$399.58M
Volume
849.68K
52W Range
$3.50 - $12.40
Target Price
$16.83
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | -- | -- | -- | $75.6M | ||
| Total Revenue | -- | -- | -- | $75.6M | ||
| GROSS PROFIT | ||||||
| Gross Profit | -- | -- | -- | $75.6M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $72.9M | $112.4M | $143.3M | $156.7M | ||
| Research & Development | $57.2M | $85.1M | $110.9M | $121.6M | ||
| Research Expense | $57.2M | $85.1M | $110.9M | $121.6M | ||
| Selling, General & Administrative | $15.7M | $27.8M | $32.0M | $35.0M | ||
| General & Administrative Expenses | $15.7M | $27.8M | $32.0M | $35.0M | ||
| Salaries & Wages | $426.0K | $568.0K | $19.6M | $22.2M | ||
| Depreciation & Amortization | $2.1M | $3.7M | $6.2M | $8.1M | ||
| Depreciation & Amortization | $2.1M | $3.7M | $6.2M | $8.1M | ||
| Amortization | -- | $3.3M | $2.1M | -- | ||
| Other Operating Expenses | $-1.3M | -- | $-2.9M | $-960.0K | ||
| OPERATING INCOME | ||||||
| Operating income | $-72.9M | $-112.4M | $-143.3M | $-81.1M | ||
| EBITDA | $-71.8M | $-105.2M | $-128.6M | $-61.8M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $9.0K | $19.0K | $198.0K | $174.0K | ||
| Intinc | $46.0K | $3.8M | $9.3M | $10.6M | ||
| Net Non-Operating Interest Income/Expense | $46.0K | $3.8M | $9.3M | $10.6M | ||
| Gain on Sale of Securities | -- | -- | $-131.0K | -- | ||
| Other Income/Expense | $960.0K | $119.0K | $-24.0K | $-10.8M | ||
| Other Special Charges | $-960.0K | -- | $8.3M | $11.0M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-73.9M | $-108.9M | $-134.8M | $-70.0M | ||
| Pre-Tax Income | $-74.0M | $-108.5M | $-135.0M | $-70.1M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | -- | $338.0K | $2.6M | ||
| NET INCOME | ||||||
| Net Income | $-74.0M | $-108.5M | $-135.4M | $-72.7M | ||
| Net Income (Continuing Operations) | $-74.0M | $-109.0M | $-135.4M | $-72.7M | ||
| Net Income (Discontinued Operations) | $-74.0M | $-108.5M | $-135.4M | $-72.7M | ||
| Net Income (Common Stockholders) | $-74.0M | $-108.5M | $-135.4M | $-72.7M | ||
| Normalized Income | $-58.4M | -- | -- | $-69.4M | ||
| TOTALS | ||||||
| Total Expenses | $72.9M | $112.4M | $143.3M | $156.7M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $25.0M | $47.2M | $51.4M | $73.9M | ||
| Average Shares Outstanding (Diluted) | -- | $47.2M | $51.4M | $73.9M | ||
| Shares Outstanding | $46.6M | $49.4M | $50.2M | $61.5M | ||
| Basic EPS | $-2.96 | $-2.3 | $-2.63 | $-0.98 | ||
| Basic EPS (Continuing Operations) | $-2.96 | $-2.3 | $-2.63 | $-0.98 | ||
| Diluted EPS | $-2.96 | $-2.3 | $-2.63 | $-0.98 | ||
| Diluted EPS (Continuing Operations) | -- | $-2.3 | $-2.63 | $-0.98 | ||
| OTHER METRICS | ||||||
| Gain On Sale Of P P E | -- | $109.0K | $24.0K | -- | ||
| Insurance And Claims | -- | $449.0K | -- | -- | ||
| Other Gand A | $15.7M | $27.8M | $32.0M | $35.0M | ||
| Rent And Landing Fees | $2.3M | $-449.0K | -- | $-170.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GLUE | $6.53 | +3.2% | 849.68K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Monte Rosa Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW